Key Takeaway: Cognition Therapeutics has reported positive results from its phase 2 SHIMMER trial for a dementia drug. These findings indicate the drug's potential effectiveness in treating dementia, marking a significant step forward for the company. The results are expected to enhance the drug's visibility and credibility in the market.
Price reaction · baseline $0.4549 (2024-12-17 close) · hit pre-market · 4 other CGTX headline(s) in the window, move may be shared
day 0 close
+27.5%
day 1
+39.4%
day 3
+35%
Market Sentiment Analysis
POSITIVE FACTORS
Cognition Therapeutics' phase 2 SHIMMER results are promising.
The dementia drug shows potential for effective treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Frequently Asked Questions
What are the SHIMMER trial results?
The SHIMMER trial results indicate promising effectiveness for Cognition's dementia drug.
What phase is the SHIMMER trial?
The SHIMMER trial is a phase 2 clinical trial.
What condition does the drug target?
The drug targets dementia.
Who conducted the SHIMMER trial?
Cognition Therapeutics conducted the SHIMMER trial.